WASHINGTON — Patiromer, a novel potassium binder, was associated with a reduction in hyperkalemia in patients with HF with reduced ejection fraction, enabling an increase in adherence to optimal medical therapy, researchers reported.
“One of the reasons why guideline-directed medical therapy is tough to achieve for renin-angiotensin-aldosterone system inhibitors, all of which are therapies associated with improvement in mortality and morbidity for patients with HFrEF, is the risk of hyperkalemia, which tends to be higher in older patients or those with comorbidities such as